• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Taming a beast: lessons from the domestication of hepatitis C virus.驯服野兽:丙型肝炎病毒驯化的启示。
Curr Opin Virol. 2019 Apr;35:27-34. doi: 10.1016/j.coviro.2019.02.008. Epub 2019 Mar 12.
2
Hepatitis C virus virology and new treatment targets.丙型肝炎病毒病毒学与新的治疗靶点
Expert Rev Anti Infect Ther. 2009 Apr;7(3):329-50. doi: 10.1586/eri.09.12.
3
Emerging antiviral drugs for hepatitis C virus.用于丙型肝炎病毒的新型抗病毒药物。
Rev Recent Clin Trials. 2009 Sep;4(3):179-84. doi: 10.2174/157488709789957628.
4
Accurate hepatitis C virus genotyping and selection of optimal therapy: lessons from a St Petersburg strain infection.丙型肝炎病毒的准确基因分型及最佳治疗方案的选择:来自圣彼得堡毒株感染的经验教训
Clin Microbiol Infect. 2018 Apr;24(4):440-441. doi: 10.1016/j.cmi.2017.10.025. Epub 2017 Dec 16.
5
Virology of hepatitis B and C viruses and antiviral targets.乙型和丙型肝炎病毒的病毒学及抗病毒靶点
J Hepatol. 2006;44(1 Suppl):S10-3. doi: 10.1016/j.jhep.2005.11.005. Epub 2005 Nov 21.
6
Novel hepatitis C drugs in current trials.当前试验中的新型丙型肝炎药物。
Clin Liver Dis. 2008 Aug;12(3):529-55, viii. doi: 10.1016/j.cld.2008.03.001.
7
Hepatitis C virus entry.丙型肝炎病毒进入。
Curr Top Microbiol Immunol. 2013;369:87-112. doi: 10.1007/978-3-642-27340-7_4.
8
Challenges and successes in developing new therapies for hepatitis C.丙型肝炎新疗法研发中的挑战与成功
Nature. 2005 Aug 18;436(7053):953-60. doi: 10.1038/nature04080.
9
Novel therapies for hepatitis C - one pill fits all?新型丙型肝炎治疗方法——一药通用?
Nat Rev Drug Discov. 2013 Aug;12(8):595-610. doi: 10.1038/nrd4050. Epub 2013 Jun 28.
10
Novel therapies for hepatitis C virus based on lessons from virology.基于病毒学经验教训的丙型肝炎病毒新型疗法。
Clin Gastroenterol Hepatol. 2005 Oct;3(10 Suppl 2):S86-8. doi: 10.1016/s1542-3565(05)00703-2.

引用本文的文献

1
A Prototype-Pathogen Approach for the Development of Flavivirus Countermeasures.基于原型病原体的方法开发黄病毒对策。
J Infect Dis. 2023 Oct 18;228(Suppl 6):S398-S413. doi: 10.1093/infdis/jiad193.
2
Gain-of-Signal Assays for Probing Inhibition of SARS-CoV-2 M/3CL in Living Cells.用于探测活细胞中 SARS-CoV-2 M/3CL 抑制的获得信号测定法。
mBio. 2022 Jun 28;13(3):e0078422. doi: 10.1128/mbio.00784-22. Epub 2022 Apr 26.
3
Analysis of antibodies from HCV elite neutralizers identifies genetic determinants of broad neutralization.分析 HCV 精英中和抗体可鉴定广谱中和的遗传决定因素。
Immunity. 2022 Feb 8;55(2):341-354.e7. doi: 10.1016/j.immuni.2021.12.003. Epub 2022 Jan 5.
4
In the era of rapid mRNA-based vaccines: Why is there no effective hepatitis C virus vaccine yet?在基于信使核糖核酸的快速疫苗时代:为什么尚无有效的丙型肝炎病毒疫苗?
World J Hepatol. 2021 Oct 27;13(10):1234-1268. doi: 10.4254/wjh.v13.i10.1234.
5
Viral hepatitis update: Progress and perspectives.病毒性肝炎最新进展:成就与展望。
World J Gastroenterol. 2021 Jul 14;27(26):4018-4044. doi: 10.3748/wjg.v27.i26.4018.
6
Gain-of-function assay for SARS-CoV-2 M inhibition in living cells.活细胞中新型冠状病毒M蛋白功能获得性抑制试验
bioRxiv. 2020 Nov 9:2020.11.09.375139. doi: 10.1101/2020.11.09.375139.
7
Reporter Replicons for Antiviral Drug Discovery against Positive Single-Stranded RNA Viruses.用于抗病毒药物发现的报道复制子:针对正单链 RNA 病毒。
Viruses. 2020 May 30;12(6):598. doi: 10.3390/v12060598.
8
Editorial overview: Antiviral strategies: Antiviral drug development for single-stranded RNA viruses.编辑概述:抗病毒策略:单链RNA病毒的抗病毒药物研发
Curr Opin Virol. 2019 Apr;35:iii-v. doi: 10.1016/j.coviro.2019.05.011. Epub 2019 May 29.

本文引用的文献

1
Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges.丙型肝炎病毒感染的直接抗病毒治疗现状及尚存挑战。
Gastroenterology. 2019 Jan;156(2):431-445. doi: 10.1053/j.gastro.2018.10.024. Epub 2018 Oct 17.
2
Hepatitis C virus cell culture models: an encomium on basic research paving the road to therapy development.丙型肝炎病毒细胞培养模型:为治疗发展铺平道路的基础研究赞歌。
Med Microbiol Immunol. 2019 Feb;208(1):3-24. doi: 10.1007/s00430-018-0566-x. Epub 2018 Oct 8.
3
Insights From Antiviral Therapy Into Immune Responses to Hepatitis B and C Virus Infection.从抗病毒治疗中洞察乙型肝炎和丙型肝炎病毒感染的免疫反应。
Gastroenterology. 2019 Jan;156(2):369-383. doi: 10.1053/j.gastro.2018.08.061. Epub 2018 Sep 26.
4
Zika virus vaccines.寨卡病毒疫苗。
Nat Rev Microbiol. 2018 Oct;16(10):594-600. doi: 10.1038/s41579-018-0039-7.
5
Protease inhibitor therapy for hepatitis C virus-infection.蛋白酶抑制剂治疗丙型肝炎病毒感染。
Expert Opin Pharmacother. 2018 Apr;19(6):577-587. doi: 10.1080/14656566.2018.1454428. Epub 2018 Mar 29.
6
Rewiring cellular networks by members of the Flaviviridae family.黄病毒科成员对细胞网络的重排。
Nat Rev Microbiol. 2018 Feb 12;16(3):125-142. doi: 10.1038/nrmicro.2017.170.
7
NS5B polymerase inhibitors in phase II clinical trials for HCV infection.用于丙型肝炎病毒感染的处于II期临床试验阶段的NS5B聚合酶抑制剂。
Expert Opin Investig Drugs. 2018 Mar;27(3):243-250. doi: 10.1080/13543784.2018.1420780. Epub 2017 Dec 28.
8
Zika Virus Pathogenesis and Tissue Tropism.寨卡病毒发病机制与组织嗜性
Cell Host Microbe. 2017 Feb 8;21(2):134-142. doi: 10.1016/j.chom.2017.01.004.
9
Tuning a cellular lipid kinase activity adapts hepatitis C virus to replication in cell culture.调节细胞脂质激酶活性可使丙型肝炎病毒适应细胞培养中的复制。
Nat Microbiol. 2016 Dec 19;2:16247. doi: 10.1038/nmicrobiol.2016.247.
10
Enter Sofosbuvir: The Path to Curing HCV.索非布韦登场:治愈丙型肝炎之路。
Cell. 2016 Sep 22;167(1):25-29. doi: 10.1016/j.cell.2016.08.044. Epub 2016 Sep 13.

驯服野兽:丙型肝炎病毒驯化的启示。

Taming a beast: lessons from the domestication of hepatitis C virus.

机构信息

The Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, United States.

The Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, United States.

出版信息

Curr Opin Virol. 2019 Apr;35:27-34. doi: 10.1016/j.coviro.2019.02.008. Epub 2019 Mar 12.

DOI:10.1016/j.coviro.2019.02.008
PMID:30875640
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6556422/
Abstract

"What I cannot create, I do not understand." Richard Feynman may have championed reasoning from first principles in his famous blackboard missive, but he could just as well have been referring to the plight of a molecular virologist. What cannot be grown in a controlled laboratory setting, we cannot fully understand. The story of the laboratory domestication of hepatitis C virus (HCV) is now a classic example of virologists applying all manner of inventive skill to create cell-based models of infection in order to clarify prospective drug targets. In this review, we highlight key successes and failures that were instructive in achieving cell-based models for HCV studies and drug development. We also emphasize the lessons learned from the ∼40 year saga that may be applicable to viruses yet unknown and uncultured.

摘要

“我不能创造的东西,我就无法理解。”理查德·费曼(Richard Feynman)在他著名的黑板便条中可能倡导了从第一原理进行推理,但他也可能指的是分子病毒学家的困境。在可控的实验室环境中无法生长的东西,我们就无法完全理解。丙型肝炎病毒(HCV)的实验室驯化故事现在是病毒学家应用各种创造性技能来创建基于细胞的感染模型以阐明潜在药物靶点的经典范例。在这篇综述中,我们强调了在建立基于细胞的 HCV 研究和药物开发模型方面具有启发性的关键成功和失败。我们还强调了从这个约 40 年的传奇故事中吸取的经验教训,这些经验教训可能适用于未知和未培养的病毒。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd42/6556422/a615c86033ac/nihms-1522086-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd42/6556422/a615c86033ac/nihms-1522086-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cd42/6556422/a615c86033ac/nihms-1522086-f0001.jpg